AI platform for precision medicine targeting intensive care
At AlgoDx, we are dedicated to developing and implementing clinically validated ML-based clinical decision support software that save lives and reduce costs in healthcare, primarily targeting intensive and critical care.
AI platform for precision medicine in intensive care
At AlgoDx, we are dedicated to developing and implementing clinically validated ML-based clinical decision support software that save lives and reduce costs in healthcare, primarily targeting intensive and critical care.
We develop software products and solutions for intensive care based on predictive analytics that aim to answer three key medical questions:
Present
How is the patient’s situation – right now?
Future
What will the patient’s situation look like in the near future?
Outcomes
What can we do to improve the patient’s outcomes?
Latest news
AlgoDx announces FDA acceptance of De Novo application for first ICU sepsis prediction algorithm.
April 13th, 2023.
AlgoDx announces today that the US Food and Drug Administration has accepted for review the company’s De Novo application for NAVOY® Sepsis, a clinical decision support software intended to assist healthcare providers at intensive care un its with predicting sepsis in adult ICU patients. Read more here.
NAVOY®
NAVOY® is our clinical decision support software that provides 24/7 autonomous and continuous sepsis risk monitoring in ICU patients to assist healthcare providers with early sepsis detection. The AlgoDx’s Platform allows the deployment of a our ML–based prediction algorithm using only routinely collected in the ICU – no additional hardware equipment or extra sampling procedures are required.
AlgoDx – proud partner with renowned stakeholders in healthcare
